European Archives - Page 1071 of 1074 - European Medical Journal

The Chemokine CCL17/TARC as a Biomarker in Hodgkin Lymphoma

Classical Hodgkin lymphoma (cHL) is a lymphoproliferative disorder hallmarked by a distinctive type of neoplastic cells, the Hodgkin and Reed/Sternberg…

Pain Management in Patients with Sickle Cell Disease - A Review

Pain is defined, by the International Association for the Study of Pain (IASP), as an ‘unpleasant sensitive and emotional experience, associated with or…

Treatment of HIV-Associated Burkitt Lymphoma

Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy, occurring with increased frequency among patients infected with HIV. For several years…

RNA Interference (RNAi): An Effective Way to Develop Rational Combination Therapies with Hypomethylating Agents in Acute Leukaemias and Myelodysplastic Syndrome

Therapeutic progress in aggressive myeloid malignancies such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and advanced…

Preventing Infections in Higher-Risk Myelodysplastic Syndrome Patients Treated with Hypomethylation Agents

Hypomethylation agents became the standard of care for patients with high-risk myelodysplastic syndrome (MDS). While long-term benefits of azacitidine…

EMJ Neurology 2013

Welcome to the first edition of European Medical Journal – Neurology. This issue will provide you with the highlights of the XXI World Congress of…

The Evolving World of Chronic Kidney Disease Mineral Bone Disorder

Chronic kidney disease – mineral and bone disorder (CKD-MBD) is associated with a significant morbidity and mortality. In vitro and animal models suggest…

EMJ Nephrology 2013

I would like to offer a very warm welcome to this first issue of European Medical Journal – Nephrology.

Clinical Proteomics: The Potentiality of Urine Analysis for Understanding Diabetic Nephropathy

The incidence of diabetic nephropathy (DN) is constantly rising in parallel with the prevalence of type 2 diabetes and has been predicted to double…

Treatment of Antibody-Mediated Rejection in Kidney Transplantation

Antibody-mediated rejection (AMR) is a relatively rare but severe complication in kidney transplantation associated with increased risk of graft loss.